Business Description
Essex Bio-Technology Ltd
NAICS : 325412
SIC : 2834
ISIN : KYG312371290
Compare
Compare
Traded in other countries / regions
01061.Hong Kong IPO Date
2001-06-27Description
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.75 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 0.71 | |||||
| Interest Coverage | 27.8 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.02 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.9 | |||||
| 3-Year EBITDA Growth Rate | 14.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year Book Growth Rate | 11.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62 | |||||
| 9-Day RSI | 62.96 | |||||
| 14-Day RSI | 61.74 | |||||
| 6-1 Month Momentum % | -16.03 | |||||
| 12-1 Month Momentum % | -41.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | |||||
| Quick Ratio | 1.46 | |||||
| Cash Ratio | 0.64 | |||||
| Days Inventory | 156.03 | |||||
| Days Sales Outstanding | 114.12 | |||||
| Days Payable | 21.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.71 | |||||
| Dividend Payout Ratio | 0.15 | |||||
| 3-Year Dividend Growth Rate | 11.9 | |||||
| Forward Dividend Yield % | 3.49 | |||||
| 5-Year Yield-on-Cost % | 4.04 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 13.57 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.2 | |||||
| Operating Margin % | 18.26 | |||||
| Net Margin % | 16.13 | |||||
| FCF Margin % | 12.37 | |||||
| ROE % | 15.12 | |||||
| ROA % | 9.87 | |||||
| ROIC % | 13.98 | |||||
| ROC (Joel Greenblatt) % | 63.45 | |||||
| ROCE % | 16.82 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 5.35 | |||||
| PE Ratio without NRI | 5.48 | |||||
| Shiller PE Ratio | 6.78 | |||||
| Price-to-Owner-Earnings | 14.34 | |||||
| PEG Ratio | 1.22 | |||||
| PS Ratio | 0.85 | |||||
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 1.78 | |||||
| Price-to-Free-Cash-Flow | 6.85 | |||||
| Price-to-Operating-Cash-Flow | 4.28 | |||||
| EV-to-EBIT | 3.48 | |||||
| EV-to-EBITDA | 2.98 | |||||
| EV-to-Revenue | 0.73 | |||||
| EV-to-FCF | 5.35 | |||||
| Price-to-Projected-FCF | 0.53 | |||||
| Price-to-DCF (Earnings Based) | 0.22 | |||||
| Price-to-DCF (FCF Based) | 0.61 | |||||
| Price-to-Median-PS-Value | 0.27 | |||||
| Price-to-Graham-Number | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 4.18 | |||||
| Earnings Yield (Greenblatt) % | 28.74 | |||||
| FCF Yield % | 14.82 | |||||
| Forward Rate of Return (Yacktman) % | 11.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Essex Bio-Technology Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 1,706.556 | ||
| EPS (TTM) (HK$) | 0.469 | ||
| Beta | 0.38 | ||
| Volatility % | 15.07 | ||
| 14-Day RSI | 61.74 | ||
| 14-Day ATR (HK$) | 0.094393 | ||
| 20-Day SMA (HK$) | 2.3435 | ||
| 12-1 Month Momentum % | -41.8 | ||
| 52-Week Range (HK$) | 1.96 - 3.7 | ||
| Shares Outstanding (Mil) | 567.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Essex Bio-Technology Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Essex Bio-Technology Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Essex Bio-Technology Ltd Frequently Asked Questions
What is Essex Bio-Technology Ltd(HKSE:01061)'s stock price today?
The current price of HKSE:01061 is HK$2.51. The 52 week high of HKSE:01061 is HK$3.70 and 52 week low is HK$1.96.
When is next earnings date of Essex Bio-Technology Ltd(HKSE:01061)?
The next earnings date of Essex Bio-Technology Ltd(HKSE:01061) is .
Does Essex Bio-Technology Ltd(HKSE:01061) pay dividends? If so, how much?
The Dividend Yield %  of Essex Bio-Technology Ltd(HKSE:01061) is 2.71% (As of Today), Highest Dividend Payout Ratio of Essex Bio-Technology Ltd(HKSE:01061) was 0.25. The lowest was 0.11. And the median was 0.14. The  Forward Dividend Yield % of Essex Bio-Technology Ltd(HKSE:01061) is 3.49%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers